This webinar covered
The momentum of ADCs has continued to assert its dominance in the oncology field throughout 2023, with a huge influx of new developers entering the space and numerous shifts in focus across payloads, combination trials, and Bispecific ADCs. In our recent webinar, we invited attendees to explore the traditional and novel ADC landscapes to maximize their pipelines and discover new opportunities that show huge potential to accelerate drug development.
- The total number of ADC programs has more than doubled in the last 2 years, what are the emerging trends from this recent influx of activity?
- From Payloads, Linkers, and Targets, to Bispecifics and Combinations, which approaches are seeing the most use and having the most impact across the ADC space?
- What were the key highlights and updates for ADC development across 2023?